Results 201 to 210 of about 68,267 (269)

Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial.

open access: yesBlood
Matino D   +59 more
europepmc   +1 more source

Impact of prophylaxis, inhibitors, and genetics on joint outcomes according to the IPSG-MRI score in hemophilia A, B and vWD type 3. [PDF]

open access: yesFront Med (Lausanne)
Seeliger A   +7 more
europepmc   +1 more source

Emicizumab prophylaxis in a preterm infant with severe hemophilia A: a case report on the feasibility of early use. [PDF]

open access: yesRes Pract Thromb Haemost
Hassan E   +6 more
europepmc   +1 more source

Balancing Promise and Peril: Hemophilia Gene Therapy Insights. [PDF]

open access: yesIUBMB Life
Akula S   +4 more
europepmc   +1 more source

[Hemophilia].

open access: yesArchives of pathology & laboratory medicine, 1976
openaire   +1 more source

Hemophilia

Pediatrics In Review, 1991
Hemophilia is a hereditary bleeding disorder characterized by Factor VIII (F-VIII) or Factor IX (F-IX) deficiency, bleeding into joints and soft tissues, and an X-linked mode of inheritance. Approximately one third of new cases occur as spontaneous mutations, with no family history of hemophilia.
J M, Lusher, I, Warrier
openaire   +2 more sources

Home - About - Disclaimer - Privacy